17 / 28
EMBRACA: Interim OS Analysis
TALA
Overall PCT
TALA
(n = 287)
PCT
(n = 144)
Events (%)
108 (38%)
55 (38%)
mOS
22.3 m
19.5 m
HR 0.76 (
0.54, 1.06);
P
= .105
Summary of Adverse Events
TALA (n = 286)
Overall PCT (n = 126)
Any AE, no. (%)
282 (98.6%)
123 (97.6%)
SAEs
91 (31.8%)
37 (29.4%)
Grade 3 or 4 serious
73 (25.5%)
32 (25.4%)
Resulting in permanent drug discontinuation
22 (7.7%)
12 (9.5%)
Litton J. SABCS 2017